Ehsan Rahimy, MD

Experts discuss the management of subretinal fluid (SRF) and intraretinal fluid (IRF) in patients with neovascular age-related macular degeneration (nAMD).

Veeral Sheth, MD, MBA, FASRS, FACS, offers clinical advice on marking disease progression in neovascular age-related macular degeneration (nAMD).

Experts offer their clinical experience and advice for applying a treat and extend strategy with anti-vascular endothelial growth factor (Anti-VEGF) injections.

Experts discuss safety data of anti-vascular endothelial growth factor (Anti-VEGF) agents while highlighting the importance of sharing this information with patients and relevant care providers.

Experts discuss strategies for educating patients, fellows, and shared-care providers on therapies and prospective outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

Experts discuss barriers that prevent optimal outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

Experts provide an overview of anti-vascular endothelial growth factor (Anti-VEGF) treatment for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.

Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.

Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.

Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.

Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.

Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.

Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.

Retina experts discuss the limitations of anti-VEGF agents in treating diabetic macular edema.

Theodore Leng, MD, FACS, describes the currently available anti-VEGF agents for treating diabetic macular edema and what factors to consider when choosing a therapy.

Ehsan Rahimy, MD, and Joseph M. Coney, MD, review the available treatment options for diabetic macular edema.

A professor of ophthalmology describes how concomitant conditions with diabetic macular edema affect the urgency of treatment regimens.

A panel of experts explains how diabetic macular edema progresses over time and how to educate patients about progression prevention.

Dr Theodore Leng reviews the preferred testing options for diabetic macular edema.

Retina specialists describe how diabetic retinopathy leads to diabetic macular edema, and the pathophysiology of the condition.

Joseph M. Coney, MD, and Theodore Leng, MD, FACS, define diabetic macular edema and explain the typical symptoms to watch for and patient referral patterns.

Key opinion leaders emphasize important considerations when discussing the safety of anti-VEGF agents with patients and highlight unmet needs in nonproliferative diabetic retinopathy treatments.

Drs Ehsan Rahimy and Joseph M. Coney analyze the implications of clinical trial data on the management of nonproliferative diabetic retinopathy.

A panel of experts reviews data on nonproliferative diabetic retinopathy treatments from the PANORAMA, Protocol W, RISE, and RIDE studies.

Dr Joseph M. Coney provides insight into the goals of therapy for patients with nonproliferative diabetic retinopathy.

Joseph M. Coney, MD, and Ehsan Rahimy, MD, explain the complications of nonproliferative diabetic retinopathy and emphasize the importance of early detection.

Drs Ehsan Rahimy and Diana V. Do define diabetic retinopathy and describe the symptoms.

Expert ophthalmologists debate the rationale behind choosing an anti-VEGF inhibitor for patients and the challenges involved in treatment management.